Top Tweets for #CTM013

about 1 year ago

🇨🇳 #NewCo deal #Lepu Biopharma (as the licensor) and #Excalipoint (as the licensee) have reached a #licensing agreement for two preclinical assets, #CTM012 and #CTM013, developed under Lepu’s proprietary T-cell engager TOPAbody platform. CTM012 and CTM013 both are #TCE, target undisclosed. CTM012 submitted IND in #China Under the agreement, Excalipoint will obtain exclusive global rights to develop and commercialize the target assets. Lepu Biopharma will receive an upfront cash payment of $10 million and ordinary shares issued by Excalipoint Cayman to Innocube, a wholly-owned subsidiary of Lepu Biopharma, representing 10% of Excalipoint Cayman’s expanded issued share capital. Additionally, Lepu Biopharma is entitled to up to $847.5 million in development and commercial milestone payments, as well as tiered sales royalties ranging from low to mid-single-digit percentages. Concurrently, Excalipoint Cayman will conduct a Series A financing, with investors including Sequoia China, YuanBio Venture Capital, and Apricot Capital collectively investing $41 million in Excalipoint Cayman. This transaction will advance Lepu Biopharma’s strategic research and development in next-generation ADC drugs and immuno-oncology bi/trispecific antibodies.

796

Top Tweets for #CTM013

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users